



B.D. p#13
1-11-00

Amdt
C

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

By Valerie A. Wilson

Date November 29, 1999

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Michael R. DeFelippis, et al.)
Serial No. : 09/096,247)
Filed : June 11, 1998) Group Art Unit:
For : Stable Insulin Formulations) 1654
Docket No. : X-10675) Examiner:
J. Russel

AMENDMENT AFTER NOTICE OF ALLOWANCE
UNDER 37 C.F.R. 1.312

Assistant Commissioner for Patents
Washington, D. C. 20231
Sir:

RECEIVED
DEC - 7 1999
CS
TECH:3

Applicants respectfully request the Examiner to enter the following amendment to the Specification under 37 C.F.R. 1.312. A notice of allowance was mailed for the above-referenced case on September 14, 1999 as Paper Number 12B. Because this amendment is being requested after allowance but before payment of the issue fee, the amendment may be entered on the recommendation of the primary examiner. The following amendment merely corrects a single typographical error in the Specification. See M.P.E.P. §714.16.


In the Specification

Page 5, line 30, change "insluin" to --insulin--.

Respectfully submitted,
Mark J. Stewart
Mark J. Stewart, Ph.D.
Attorney for Applicants
Registration No. 43,936
Phone: 317-276-0280

Eli Lilly and Company
Patent Division/MJS
Lilly Corporate Center
Indianapolis, Indiana 46285

November 24, 1999



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

ELI LILLY AND COMPANY

By

Valerie A. Wilson

Date

November 29, 1999

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Michael R. DeFelippis, et al.)
Serial No. : 09/096,247)
Filed : June 11, 1998) Group Art Unit:
For : Stable Insulin Formulations) 1654
Docket No. : X-10675) Examiner:
J. Russel

AMENDMENT AFTER NOTICE OF ALLOWANCE
UNDER 37 C.F.R. 1.312

Assistant Commissioner for Patents
Washington, D. C. 20231
Sir:

Applicants respectfully request the Examiner to enter the following amendment to the Specification under 37 C.F.R. 1.312. A notice of allowance was mailed for the above-referenced case on September 14, 1999 as Paper Number 12B. Because this amendment is being requested after allowance but before payment of the issue fee, the amendment may be entered on the recommendation of the primary examiner. The following amendment merely corrects a single typographical error in the Specification. See M.P.E.P. §714.16.


In the Specification

Page 5, line 30, change "insluin" to "--insulin--".

Respectfully submitted,
Mark J. Stewart
Mark J. Stewart, Ph.D.
Attorney for Applicants
Registration No. 43,936
Phone: 317-276-0280

Eli Lilly and Company
Patent Division/MJS
Lilly Corporate Center
Indianapolis, Indiana 46285

November 24, 1999



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

By

Valerie A. Wilson

Date

November 29, 1999

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Michael R. DeFelippis, et al.)	
Serial No.	:	09/096,247)	
Filed	:	June 11, 1998)	Group Art Unit:
)	1654
For	:	Stable Insulin Formulations)	Examiner:
)	J. Russel
Docket No.	:	X-10675)	

AMENDMENT AFTER NOTICE OF ALLOWANCE
UNDER 37 C.F.R. 1.312

Assistant Commissioner for Patents
Washington, D. C. 20231
Sir:

Applicants respectfully request the Examiner to enter the following amendment to the Specification under 37 C.F.R. 1.312. A notice of allowance was mailed for the above-referenced case on September 14, 1999 as Paper Number 12B. Because this amendment is being requested after allowance but before payment of the issue fee, the amendment may be entered on the recommendation of the primary examiner. The following amendment merely corrects a single typographical error in the Specification. See M.P.E.P. §714.16.

In the Specification

Page 5, line 30, change "insluin" to --insulin--.

Respectfully submitted,
Mark J. Stewart
Mark J. Stewart, Ph.D.
Attorney for Applicants
Registration No. 43,936
Phone: 317-276-0280

Eli Lilly and Company
Patent Division/MJS
Lilly Corporate Center
Indianapolis, Indiana 46285

November 24, 1999